Market Place
Sourcing Support
Verona Pharma to Attend December 2024 Investor Conference
19 Nov 2024 //
GLOBENEWSWIRE
BC Platforms, Modirum, VEIL.AI Publish EHDS2 Framework
05 Nov 2024 //
GLOBENEWSWIRE
Verona Pharma Reports Q3 2024 Results and Corporate Update
04 Nov 2024 //
GLOBENEWSWIRE
Verona Pharma Reports Q3 2024 Financials, Corporate Update
21 Oct 2024 //
GLOBENEWSWIRE
Verona Pharma Presents Ph 3 ENHANCE studies In COPD At CHEST 2024
30 Sep 2024 //
GLOBENEWSWIRE
Ritedose Partners With Verona To Deliver First-In-Class COPD Drug Ohtuvayre
17 Sep 2024 //
PR NEWSWIRE
Verona Pharma To Present Ph3 COPD Study Analyses At ERS Congress
05 Sep 2024 //
GLOBENEWSWIRE
Verona Pharma Reports Q2 2024 Results And Corporate Update
08 Aug 2024 //
GLOBENEWSWIRE
Verona Pharma to Present at 44th Annual Canaccord Growth Conference
30 Jul 2024 //
GLOBENEWSWIRE
Verona Pharma To Report Q2 2024 Results And Give Corporate Update
24 Jul 2024 //
GLOBENEWSWIRE
Verona`s price for COPD drug far exceeds ICER`s valuation
16 Jul 2024 //
FIERCE PHARMA
US FDA approves Verona Pharma`s inhaled COPD therapy
27 Jun 2024 //
REUTERS
Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)
26 Jun 2024 //
GLOBENEWSWIRE
Verona`s Ensifentrine Called `Paradigm Shift` For COPD By GlobalData
30 May 2024 //
FIERCE PHARMA
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
10 May 2024 //
PRESS RELEASE
Verona Pharma Q1 2024 Financials And Corporate Update
09 May 2024 //
GLOBENEWSWIRE
Verona To Present More COPD Phase 3 ENHANCE Data At ATS
02 May 2024 //
GLOBENEWSWIRE
Verona Pharma to Report Q1 2024 Results, Corporate Update
25 Apr 2024 //
GLOBENEWSWIRE
Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results
15 Feb 2024 //
GLOBENEWSWIRE
Michael Austwick Joins Verona Pharma as Non-Executive Director
01 Feb 2024 //
GLOBENEWSWIRE
Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
GLOBENEWSWIRE
Verona secures $400M financing arrangement with Oxford
02 Jan 2024 //
ENDPTS
Verona Pharma™s President and CEO David Zaccardelli Wins SCRIP Award
17 Nov 2023 //
GLOBENEWSWIRE
Verona Pharma Announces November 2023 Investor Conference Participation
08 Nov 2023 //
GLOBENEWSWIRE
Verona Pharma Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
Verona Pharma to Report Third Quarter 2023 Financial Results
19 Oct 2023 //
GLOBENEWSWIRE
Verona Pharma to Host Update on Commercialization Preparation for Ensifentrine
06 Oct 2023 //
GLOBENEWSWIRE
Verona Pharma to Present Analyses of Positive Phase 3 ENHANCE Studies
02 Oct 2023 //
GLOBENEWSWIRE
Verona Pharma Announces the US FDA has Accepted the NDA Filing for Ensifentrine
11 Sep 2023 //
GLOBENEWSWIRE
Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD
06 Sep 2023 //
GLOBENEWSWIRE
Verona Pharma Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
Verona Pharma to Present at 43rd Annual Canaccord Growth Conference
26 Jul 2023 //
GLOBENEWSWIRE
Verona Pharma to Report Q2 2023 Financial Results and Provide Corporate Update
20 Jul 2023 //
GLOBENEWSWIRE
Verona Pharma Announces Publication of Phase 3 ENHANCE Data
28 Jun 2023 //
GLOBENEWSWIRE
Verona Pharma submits FDA New Drug Application for COPD treatment
27 Jun 2023 //
PHARMAFILE
Verona Pharma to Present at Jefferies Healthcare Conference
24 May 2023 //
GLOBENEWSWIRE
Verona Pharma Reports1Q 2023 FYR and Provides Corporate Update
09 May 2023 //
GLOBENEWSWIRE
Verona to Present Expanded Analyses of Positive Phase 3 ENHANCE Studie
02 May 2023 //
BIOSPACE
Verona Pharma to Report 1Q 2023 FYR and Provide Corporate Update
25 Apr 2023 //
GLOBENEWSWIRE
Verona Reports Fourth Quarter and Full Year 2022 Financial Results
07 Mar 2023 //
GLOBENEWSWIRE
Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results
21 Feb 2023 //
GLOBENEWSWIRE
Second PIII win for Verona`s ensifentrine in COPD sets up FDA filing
21 Dec 2022 //
ENDPTS
Verona Pharma Announces Ensifentrine Meets Primary & Key Secondary Endpoints
20 Dec 2022 //
GLOBENEWSWIRE
Verona Pharma Reports3Q 2022 Financial Results and Provides Corporate Update
08 Nov 2022 //
GLOBENEWSWIRE
Verona Pharma Announces November 2022 Investor Conference Participation
01 Nov 2022 //
GLOBENEWSWIRE
Verona to Report Third Quarter 2022 Financial Results & Provide Corporate Update
26 Oct 2022 //
GLOBENEWSWIRE
Pfizer nabs equity stake in biotech; Verona gets cash after COPD win
18 Oct 2022 //
ENDPTS
Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance
17 Oct 2022 //
GLOBENEWSWIRE
Verona Announces Analyses Demonstrating Ensifentrine ReducedExacerbation Rates
13 Oct 2022 //
GLOBENEWSWIRE
Verona Pharma to Present at H.C. Wainwright 24th Annual Global InvT
29 Aug 2022 //
GLOBENEWSWIRE
Verona Pharma Enhances Commercialization Leadership Team
24 Aug 2022 //
CONTRACTPHARMA
Nuance Pharma Announces Clearance of IND Application for Ensifentrine Trials
18 Aug 2022 //
PRNEWSWIRE
Verona Pharma plc Announces Closing of Upsized Underwritten Public Offering.
15 Aug 2022 //
GLOBENEWSWIRE
Verona Pharma plc Announces Pricing of Upsized Underwritten Public Offering
10 Aug 2022 //
GLOBENEWSWIRE
Verona Pharma Announces Ensifentrine Meets Primary Endpoint in PIII for COPD
09 Aug 2022 //
GLOBENEWSWIRE
Verona Pharma Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
GLOBENEWSWIRE
Verona Pharma plc Announces Proposed Underwritten Public Offering
09 Aug 2022 //
GLOBENEWSWIRE
Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-2 Trial
08 Aug 2022 //
GLOBENEWSWIRE
Verona Pharma to Report Second Quarter 2022 Financial Results
29 Jul 2022 //
GLOBENEWSWIRE
Verona Pharma Completes Enrollment in PIII ENHANCE-1 Trial of Ensifentrine
09 Jun 2022 //
GLOBENEWSWIRE
